The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Rituximab for RA Is Safe Long Term, Plus Oxycodone Update

Rituximab for RA Is Safe Long Term, Plus Oxycodone Update

September 30, 2015 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

GENERIC_Drugs_500x270Long-Term Rituximab Safety in Rheumatoid Arthritis
Ronald F. van Vollenhoven, MD, PhD, chief of the Unit for Clinical Therapy Research, Inflammatory Diseases at the Karolinska Institute in Stockholm, Sweden, and colleagues evaluated the long-term safety of rituximab (RTX) in patients who have had moderate to severe, active rheumatoid arthritis (RA) for up to 11 years.1

You Might Also Like
  • FDA Update: Committees Recommend Approvals for Abuse-Deterrent Opioid & Brodalumab
  • FDA to Review Abuse Deterrent Oxycodone Capsule & More
  • Oxycodone Capsules Put on Hold; Clinical Trials for Lupus Nephritis & SLE Therapies
Also By This Author
  • FDA Expands Label for Insulin Degludec; Adalimumab Biosimilar Moves Forward After Legal Battle

Patients were on combination treatment with RTX and methotrexate (MTX). This study was a pooled case analysis of patients in a global clinical trial program that included eight randomized clinical trials; two long-term, open-label extensions; and one open-label prospective study.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

As of September 2012, 3,595 patients had received a mean of four RTX courses (range 1–20) over 11 years. Of these 3,595 patients, 1,246 had more than five years of follow-up (8,970 PY). A pooled placebo population (n=818) was included in the analysis.

Adverse event (AE) and serious adverse event (SAE) data were similar among all populations: RTX all exposure (n=3,595), RTX long term (n=1,246) and placebo treated (n=818). The overall serious infection event (SIE) rate was 3.76/100 patient-years (PY; 2.71/100 PY in patients observed for over five years). This result was comparable to previously reported rates at 9.5 years (3.94/100 PY and 3.26/100 PY, respectively).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Serious opportunistic infection rates were rare. Cardiac event rates remained consistent with previous analyses and similar to rates in the general RA population. The most common cardiac AE was myocardial infarction, which occurred in 51 patients. Most of these patients had at least one risk factor for the event. There was no increased risk of malignancy observed over time. Two hundred and forty-one patients (7%) in the all-exposure population prematurely withdrew from their respective study due to AEs and SAEs. The incidence was higher in the first course of treatment and decreased thereafter with each subsequent treatment course.

This report shows that RTX is well tolerated over time and following multiple courses. No new safety risks were identified, and there was no increase in the rate of any AE type with prolonged RTX exposure for up to 11 years of observation.

FDA Advisory Committee Update
On Sept. 10 at the joint meeting of the FDA’s Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee, members voted 23-to-1 against approving Purdue Pharma’s Avridi, the first potential immediate release (IR) oxycodone tablet with abuse-deterrent properties.2 Research showed that participants who took this formulation after meals had a lower oxycodone serum concentration with a delayed analgesic effect.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: Analgesics, Biologics & Biosimilars, Drug Updates Tagged With: analgesic, FDA, Food and Drug Administration, Oxycodone, Rheumatoid Arthritis (RA), rituximab

You Might Also Like:
  • FDA Update: Committees Recommend Approvals for Abuse-Deterrent Opioid & Brodalumab
  • FDA to Review Abuse Deterrent Oxycodone Capsule & More
  • Oxycodone Capsules Put on Hold; Clinical Trials for Lupus Nephritis & SLE Therapies
  • FDA to Review Immediate-Release Oxycodone; Plus NICE Recommends Secukinumab

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)